Catalyst

Slingshot members are tracking this event:

FDA Expands Indication of INVOKAMET (canagliflozin/metformin HCl) to Include First-Line Treatment of Adults with Type 2 Diabetes

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
Janssen Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 24, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Invokamet, Canagliflozin, Metformin Hcl, Type 2 Diabetes